1-4 of 4
Saurabh Ray
Close
Sort by
Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 382.
https://doi.org/10.1182/blood-2019-123554
Published: 2019
Journal Articles

Real-World Differences in Characteristics and Survival of Relapsed AML Patients with and without Transplant

Abdalla Aly, Saurabh Ray, Anuj Shah, PhD, Marc Botteman, MS, MA
Journal: Blood
Blood (2018) 132 (Supplement 1): 2297.
https://doi.org/10.1182/blood-2018-99-118621
Published: 2018
Journal Articles

Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

Abdalla Aly, PhD, Bela Bapat, MA, Saurabh Ray, PhD, Zhiyong Chen, PhD, Marc Botteman, MSc, MA
Journal: Blood
Blood (2017) 130 (Supplement 1): 3386.
https://doi.org/10.1182/blood.V130.Suppl_1.3386.3386
Published: 2017
Journal Articles

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Annie Guerin, MSc, Saurabh Ray, PhD, Genevieve Gauthier, MSc, Ling-I Hsu, PhD, Maryia Zhdanava, Eric Wu, PhD
Journal: Blood
Blood (2015) 126 (23): 3313.
https://doi.org/10.1182/blood.V126.23.3313.3313
Published: 2015